CAMR – No problems with the WTO

The hearings into Bill S-232 on reforming Canada’s Access to Medicines Regime continued in the Senate Banking, Trade and Commerce committee. Both witnesses today appeared by teleconference – one from Geneva, the other from the University of Florida.

First up was Antony Taubman, Director of International Property Division of the WTO, and while he wasn’t in a position to offer any opinions on the legislation itself, he gave a great deal of background into the WTO agreements that allowed for the creation of CAMR and similar legislation. From this particular round of questions, we learned that if – and it’s a big if – these amended CAMR provisions were indeed contrary to WTO provisions, there is no automatic policing method. There would have to be a complaint from a member country for it to head to a bilateral dispute resolution mechanism. Taubman also pointed out that while the current legislation may have little take-up with the existing pharmacopoeia, it is likely to be more useful with second generation drugs that countries like India face additional patent protections on.

The second witness was Frederick M. Abbott, the Edward Ball Eminent Scholar and Professor of International Law at the Florida State University College of Law. He’s been involved in these issues for years, and in fact testified in the House of Commons committee when the first CAMR bill was passed, and he had reservations then that it didn’t go far enough. This bill proves that he was right.

According to Abbott, the bill would change the bargaining conditions by which generic drug manufacturers negotiate with patent holders and developing nations in order to supply them these medicines. By streamlining this process, it allows them to engage in economies of scale, which then allows them to become more competitive. Hmm. Didn’t we hear this before? From Apotex maybe?

Abbott also made the point that if our generic drug industry was so expensive and inefficient, then it wouldn’t still exist because of competition factors. He also noted that this bill fixes most of his concerns with the original CAMR legislation, so he’s very much in favour of keeping it as is.

Keep Reading

The new generation of gay Conservative sellouts

OPINION: Melissa Lantsman’s and Eric Duncan’s refusals to call out their party’s transphobia is a betrayal of the LGBTQ2S+ community

Over 300 anti-LGBTQ2S+ bills have been introduced this year. This doesn’t mean we should panic

OPINION: While it’s important to watch out for threats, not all threats are created equally. Some of these bills will die a natural death

Xtra’s top LGBTQ2S+ stories of the year

The best and brightest—even most bewildering—stories from a back catalogue brimming with insight

Elon Musk and Texas attorney general Ken Paxton are suing Media Matters. Here’s why queer and trans people should care

OPINION: When politicians and the rich leverage the power of the state to quell dissent, we all lose